Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Immunoprecise Antibodies Ltd IPA

Healthcare Biotechnology
ImmunoPrecise Antibodies Ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies. It has several subsidiaries in North America and Europe including entities, such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the IPA Family). Its Contract Research Organizations (CRO) services include B cell Select; Phage Display; DeepDisplay; Abthena Bispecifics; LucinaTech Humanization; Affinity Maturation; Immunization, hybridoma, sequencing; rPEx protein manufacturing, and Cell line development. The Company utilizes custom antigen modeling, target analysis using Natural Language Processing and the HYFTTM analysis to lay the groundwork for the subsequent experimental phases.


NDAQ:IPA - Post by User

Immunoprecise Antibodies Ltd > Interesting post yesterday on.... ceo.ca ipa
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(737)
•••
Comment by mercedesmanon Dec 31, 2021 9:15pm
136 Views
Post# 34275487

RE:RE:Interesting post yesterday on.... ceo.ca ipa

RE:RE:Interesting post yesterday on.... ceo.ca ipa

wallpaper2 wrote: Samsung is denying the Korean report based on a interview from a senior official at a global Investment Bank. Biogen will not comment and their stock rose 9.5% on the report??  Biogen was in partnership with Samsung prior to this weeks news report in the "Korea Economic Daily."
Samsung said in Sept 2021 they would invest $200 billion in Biopharmaceuticals, semi conductors, and AI over the next 3 years.


I think that throwing just one of those billions our way ( USD of course) would be a reasonable albeit speculative bet.  Good enough for a 12 bagger for us! 

2022 will be their year!

MM
 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities